Inhibitors of lipogenic enzymes as a potential therapy against cancer.

School of Chemical Sciences and Engineering, Yachay Tech University, San Miguel de Urcuquí, Ecuador. Department of Inorganic and Organic Chemistry, School of Chemistry, Universitat de Barcelona, Barcelona, Spain. Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, Barcelona, Spain.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2020;(9):11355-11381
Full text from:

Other resources

Abstract

Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs.

Methodological quality

Publication Type : Review

Metadata